Thus, there is a critical need to further study CD8 and CD4 T cell function, phenotype, and myeloma-specific immunity within the BM TME of myeloma patients after ASCT in order to define the optimal timing for immunotherapy approaches. The gene discussed is CD8A; the disease is plasma cell myeloma.